Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data

Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data

Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life.The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone aceta...

Full description

Bibliographic Details
Main Authors: Yasmine Rhanine, Hervé Bonnefoi, Anthony Goncalves, Marc Debled, Sylvestre Le Moulec, Nathalie Bonichon, Gaetan Macgrogan, Monica Arnedos, Bénédicte Dubroca-Dehez, Thomas Grellety
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Breast
Subjects:
Androgen receptor-positive triple-negative breast cancer
Antiandrogens
Real-life data
Androgen receptor
Biomarker
Clinical benefit rate
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977623007932

Internet

http://www.sciencedirect.com/science/article/pii/S0960977623007932

Similar Items